Irbesartan Sandoz (Irbesartan)

Irbesartan works by selectively blocking the angiotensin II type 1 (AT1) receptor. This prevents angiotensin II from causing blood vessels to narrow and from stimulating aldosterone release, resulting in vasodilation, reduced blood volume, lower blood pressure, and decreased pressure within the kidneys.

The appropriate dose of Irbesartan Sandoz is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and other medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Irbesartan is classified as Pregnancy Category D, indicating evidence of fetal risk. It should not be used during pregnancy. Limited data are available for breastfeeding; therefore, the drug should be used only if the potential benefit justifies the possible risk to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, which generally offers similar blood‑pressure‑lowering efficacy to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with other ARBs, its pharmacokinetic profile and dosing flexibility are comparable, making it a suitable alternative for patients intolerant to ACE inhibitors.

Irbesartan Sandoz tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Irbesartan Sandoz is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious risks include angioedema, severe hyperkalaemia, and acute kidney injury, especially when combined with other drugs that affect potassium or renal function. Patients should be monitored for swelling of the face or throat, rapid changes in blood pressure, and abnormal laboratory values.

Irbesartan should not be used by individuals with known hypersensitivity to irbesartan or any component of the formulation, pregnant women, or patients with severe hepatic impairment. Caution is also advised for those with bilateral renal artery stenosis or uncontrolled hyperkalaemia.